References

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.

10.1136/gutjnl-2022-327745 · 2022 · External reference

ACG clinical guideline: treatment of Helicobacter pylori infection.

10.14309/ajg.0000000000002968 · 2024 · External reference

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

10.1136/gutjnl-2015-311304 · 2016 · External reference

Kyoto global consensus report on Helicobacter pylori gastritis.

10.1136/gutjnl-2015-309252 · 2015 · External reference

Helicobacter pylori treatment in the era of increasing antibiotic resistance.

10.1136/gut.2009.192757 · 2010 · External reference

Tegoprazan dual and quadruple therapy for Helicobacter pylori eradication: a prospective, randomized controlled trial in Beijing, China.

10.3389/fmed.2025.1629567 · 2025 · External reference

Fourteen-and ten-day tegoprazan–amoxicillin dual therapy vs. bismuth quadruple therapy for Helicobacter pylori eradication – a noninferiority, multicenter, randomized controlled trial.

10.1111/jgh.70180 · 2025 · External reference

Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan: a randomized controlled multicenter study.

10.14309/ctg.0000000000000699 · 2024 · External reference

Tegoprazan–amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, randomized, multicenter study in Fujian, China.

10.1111/hel.13151 · 2024 · External reference

Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China.

10.1177/17562848251391276 · 2025 · External reference

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.

10.1136/gutjnl-2019-319954 · 2020 · External reference

Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial.

10.5009/gnl220055 · 2022 · External reference

Fourteen-day tegoprazan–amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection (SHARE2301): a multicenter, noninferiority, randomized clinical trial.

10.1111/hel.13098 · 2024 · External reference

High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis.

10.5152/tjg.2022.21579 · 2022 · External reference